Pharmacies compounding Semaglutide raises concerns

Pharmacies compounding Semaglutide raises concerns

The US Food and Drug Administration (FDA) recently warned two online suppliers to stop manufacturing unapproved versions of semaglutide (marketed as Ozempic for type 2 diabetes). 2; Wegovy for obesity) and tirzepatide (Mounjaro). With ongoing shortages of these two popular drugs, compounded versions have become popular. According to the FDA, compounding pharmacies are allowed to … Read more